Abstract
60 - Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have